4151-A UNMET SYSTEMIC THERAPY NEED FOR CHILD-PUGH CLASS B PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA COMPARISON OF ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB Hideko Ohama 1,2,3 , Atsushi Hiraoka 1,2 , Toshifumi Tada 2 , Masashi Hirooka 2 , Kazuya Kariyama 2 , Ei Itobayashi 2 , Tsuji Kunihiko 2 , Toru Ishikawa 2 , Hidenori Toyoda 2 , Takeshi Hatanaka 2 , Satoru Kakizaki 2 , Atsushi Naganuma 2 , Tomomitsu Matono 2 , Fujimasa Tada 1,2 , Kazuhiro Nouso 2 , Yoichi Hiasa 2 and Takashi Kumada 2 , (1)Ehime Prefectural Central Hospital, (2)Relpec Study Group and HCC 48 Group, (3)Takarazuka City Hospital Background: Systemic treatment is generally recommended for unresectable hepatocellular carcinoma (uHCC) patients with Child-Pugh (CP)-A status
The following section describes and summarizes these drugs in terms of the mechanisms by which they activate the GSH system (Table 3, Supplementary Table S3)
Many individuals utilize liposomal glutathione as an essential part of their anti aging beauty routine
Superoxide radicals generated by electron leakage are damaging in their own right, but they can react with nitric oxide (NO) generated by nitric oxide synthase to generate highly reactive peroxynitrite (ONOO )
